Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naïve to antiretroviral therapy

Journal of General Virology

Volumn 93, Issue PART 10, 2012, Pages 2267-2278

  Hu, Xintao ^a   Hong, Kunxue ^a   Zhao, Chunhong ^a   Zheng, Yang ^a   Ma, Liying ^a   Ruan, Yuhua ^a   Gao, Hongmei ^b   Greene, Kelli ^b   Sarzotti Kelsoe, Marcella ^b   Montefiori, David C ^b   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIBODY RESPONSE; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINA; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS STRAIN;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD DONORS; CD4 LYMPHOCYTE COUNT; CELL LINE, TUMOR; CHINA; COHORT STUDIES; CROSS REACTIONS; FEMALE; HELA CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; VIRAL LOAD; VIRAL VACCINES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84866314695     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.043802-0     Document Type: Article

References (54)

1. Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A., Posner, M. R., Katinger, H. & other authors (2000). Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6, 200-206.
2. Binley, J. M., Lybarger, E. A., Crooks, E. T., Seaman, M. S., Gray, E., Davis, K. L., Decker, J. M., Wycuff, D., Harris, L. & other authors (2008). Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82, 11651-11668.
3. Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A. & Wyatt, R. T. (2004). HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5, 233-236.
4. Doria-Rose, N. A., Klein, R. M., Manion, M. M., O'Dell, S., Phogat, A., Chakrabarti, B., Hallahan, C. W., Migueles, S. A., Wrammert, J. & other authors (2009). Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83, 188-199.
5. Doria-Rose, N. A., Klein, R. M., Daniels, M. G., O'Dell, S., Nason, M., Lapedes, A., Bhattacharya, T., Migueles, S. A., Wyatt, R. T. & other authors (2010). Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 84, 1631-1636.
6. Ehrlich, H. J., Müller, M., Oh, H. M., Tambyah, P. A., Joukhadar, C., Montomoli, E., Fisher, D., Berezuk, G., Fritsch, S. & other authors (2008). A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358, 2573-2584.
7. Galli, G., Medini, D., Borgogni, E., Zedda, L., Bardelli, M., Malzone, C., Nuti, S., Tavarini, S., Sammicheli, C. & other authors (2009). Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 106, 3877-3882.
8. Gray, E. S., Taylor, N., Wycuff, D., Moore, P. L., Tomaras, G. D., Wibmer, C. K., Puren, A., DeCamp, A., Gilbert, P. B. & other authors (2009). Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype Cinfected blood donors. J Virol 83, 8925-8937.
9. Gray, E. S., Madiga, M. C., Hermanus, T., Moore, P. L., Wibmer, C. K., Tumba, N. L., Werner, L., Mlisana, K., Sibeko, S. & other authors (2011). The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 85, 4828-4840.
10. Hessell, A. J., Rakasz, E. G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D. N., Koff, W. C., Watkins, D. I. & Burton, D. R. (2009). Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5, e1000433.
11. Hoxie, J. A. (2010). Toward an antibody-based HIV-1 vaccine. Annu Rev Med 61, 135-152.
12. Kaufman, J. & Jing, J. (2002). China and AIDS-the time to act is now. Science 296, 2339-2340.
13. Kwong, P. D., Doyle, M. L., Casper, D. J., Cicala, C., Leavitt, S. A., Majeed, S., Steenbeke, T. D., Venturi, M., Chaiken, I. & other authors (2002). HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682.
14. Lakhashe, S. K., Kulkarni, S. S., Thakar, M. R., Ghate, M. V. & Paranjape, R. S. (2007). Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1. Virology 359, 295-301.
15. Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P. & other authors (2005). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79, 10108-10125.
16. Li, M., Salazar-Gonzalez, J. F., Derdeyn, C. A., Morris, L., Williamson, C., Robinson, J. E., Decker, J. M., Li, Y., Salazar, M. G. & other authors (2006). Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80, 11776-11790.
17. Li, Y., Migueles, S. A., Welcher, B., Svehla, K., Phogat, A., Louder, M. K., Wu, X., Shaw, G. M., Connors, M. & other authors (2007). Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13, 1032-1034.
18. Long, E. M., Rainwater, S. M., Lavreys, L., Mandaliya, K. & Overbaugh, J. (2002). HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 18, 567-576.
19. Lu, S., Grimes Serrano, J. M. & Wang, S. (2010). Polyvalent AIDS vaccines. Curr HIV Res 8, 622-629.
20. Mahalanabis, M., Jayaraman, P., Miura, T., Pereyra, F., Chester, E. M., Richardson, B., Walker, B. & Haigwood, N. L. (2009). Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol 83, 662-672.
21. Mascola, J. R. & Montefiori, D. C. (2003). HIV-1: nature's master of disguise. Nat Med 9, 393-394.
22. Mascola, J. R. & Montefiori, D. C. (2010). The role of antibodies in HIV vaccines. Annu Rev Immunol 28, 413-444.
23. Mascola, J. R., Louder, M. K., Surman, S. R., Vancott, T. C., Yu, X. F., Bradac, J., Porter, K. R., Nelson, K. E., Girard, M. & other authors (1996). Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 12, 1319-1328.
24. Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S. & other authors (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6, 207-210.
25. Mikell, I., Sather, D. N., Kalams, S. A., Altfeld, M., Alter, G. & Stamatatos, L. (2011). Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 7, e1001251.
26. Moir, S. & Fauci, A. S. (2009). B cells in HIV infection and disease. Nat Rev Immunol 9, 235-245.
27. Montefiori, D. C. (2005). Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 64, 12.11.1-12.11.17.
28. Nair, N., Gans, H., Lew-Yasukawa, L., Long-Wagar, A. C., Arvin, A. & Griffin, D. E. (2007). Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 196, 1339-1345.
29. Ozaki, D. A., Gao, H., Todd, C. A., Greene, K. M., Montefiori, D. C. & Sarzotti-Kelsoe, M. (2012). International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. PLoS ONE 7, e30963.
30. Parren, P. W., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P. & Burton, D. R. (2001). Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75, 8340-8347.
31. Phogat, S. & Wyatt, R. (2007). Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des 13, 213-227.
32. Piantadosi, A., Panteleeff, D., Blish, C. A., Baeten, J. M., Jaoko, W., McClelland, R. S. & Overbaugh, J. (2009). Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 83, 10269-10274.
33. Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B. & Kabat, D. (1998). Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72, 2855-2864.
34. Poss, M. & Overbaugh, J. (1999). Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J Virol 73, 5255-5264.
35. Sather, D. N., Armann, J., Ching, L. K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S. & other authors (2009). Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83, 757-769.
36. Scheid, J. F., Mouquet, H., Feldhahn, N., Seaman, M. S., Velinzon, K., Pietzsch, J., Ott, R. G., Anthony, R. M., Zebroski, H. & other authors (2009). Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636-640.
37. Schlereth, B., Rose, J. K., Buonocore, L., ter Meulen, V. & Niewiesk, S. (2000). Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 74, 4652-4657.
38. Seaman, M. S., Janes, H., Hawkins, N., Grandpre, L. E., Devoy, C., Giri, A., Coffey, R. T., Harris, L., Wood, B. & other authors (2010). Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84, 1439-1452.
39. Shibata, R., Igarashi, T., Haigwood, N., Buckler-White, A., Ogert, R., Ross, W., Willey, R., Cho, M. W. & Martin, M. A. (1999). Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5, 204-210.
40. Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T. & other authors (2009). Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a highthroughput neutralization assay together with an analytical selection algorithm. J Virol 83, 7337-7348.
41. Su, B., Liu, L., Wang, F., Gui, X., Zhao, M., Tien, P., Zhang, L. & Chen, Z. (2003). HIV-1 subtype B9 dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China. AIDS 17, 2515-2520.
42. Tibshirani, R., Walther, G. & Hastie, T. (2001). Estimating the number of clusters in a data set via the gap statistic. J R Stat Soc B 63, 411-423.
43. Todd, C. A., Greene, K. M., Yu, X., Ozaki, D. A., Gao, H., Huang, Y., Wang, M., Li, G., Brown, R. & other authors (2012). Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J Immunol Methods 375, 57-67.
44. Tomaras, G. D., Binley, J. M., Gray, E. S., Crooks, E. T., Osawa, K., Moore, P. L., Tumba, N., Tong, T., Shen, X. & other authors (2011). Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 85, 11502-11519.
45. Trkola, A., Kuster, H., Rusert, P., Joos, B., Fischer, M., Leemann, C., Manrique, A., Huber, M., Rehr, M. & other authors (2005). Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11, 615-622.
46. van Gils, M. J., Bunnik, E. M., Burger, J. A., Jacob, Y., Schweighardt, B., Wrin, T. & Schuitemaker, H. (2010a). Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J Virol 84, 3576-3585.
47. van Gils, M. J., Edo-Matas, D., Schweighardt, B., Wrin, T. & Schuitemaker, H. (2010b). High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity. J Gen Virol 91, 250-258.
48. Veazey, R. S., Shattock, R. J., Pope, M., Kirijan, J. C., Jones, J., Hu, Q., Ketas, T., Marx, P. A., Klasse, P. J. & other authors (2003). Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9, 343-346.
49. Wang, S. H., Xing, H., Wang, J. J., Su, B., Chen, X., Quan, Y., Zhao, Q. B., Ruan, Y. H., Xu, J. Q. & other authors (2007). Sequence analysis of gag and env genes of HIV type 1 circulating in former blood donors of Fuyang city, Anhui province. Zhonghua Yi Xue Za Zhi 87, 1535-1539 (in Chinese).
50. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M. & Kappes, J. C. (2002). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46, 1896-1905.
51. Wu, X., Yang, Z. Y., Li, Y., Hogerkorp, C. M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L. & other authors (2010). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861.
52. Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N. S., Louder, M. & other authors (2011). Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602.
53. Xu, J. Q., Wang, J. J., Han, L. F., Xu, C., Ruan, Y. H., Xu, Z. H., Chen, X., Liu, Z. D., Wang, J. & other authors (2006). Epidemiology, clinical and laboratory characteristics of currently alive HIV-1 infected former blood donors naive to antiretroviral therapy in Anhui Province, China. Chin Med J (Engl) 119, 1941-1948.
54. Zhang, X., Xu, J., Peng, H., Ma, Y., Han, L., Ruan, Y., Su, B., Wang, N. & Shao, Y. (2008). HCV coinfection associated with slower disease progression in HIV-infected former plasma donors naïve to ART. PLoS ONE 3, e3992.